Business Context and Reporting Period
This Form 8-K Current Report was filed by Revelation Biosciences, Inc. on May 23, 2025. The report discloses a corporate governance event involving the resignation of a member of the Board of Directors.
Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Board Composition: The Board of Directors size was reduced from five (5) to four (4) members.
- Director Resignation: George Tidmarsh, M.D., Ph.D., resigned from the Board on May 23, 2025.
- Class Reclassification: Lakhmir Chawla, M.D., has been reclassified as a Class C Director to maintain the board's class structure.
Guidance, Outlook, and Risks
Management Commentary: The Company stated that Dr. Tidmarsh's resignation was not the result of any disagreements with the Company regarding its operations, policies, or practices. Dr. Tidmarsh served as a Class C Director with a term set to expire at the 2025 Annual Meeting of Stockholders.
Risks and Contingencies: No specific financial risks, contingencies, or unusual items were disclosed in this filing. The filing notes that the press release regarding the resignation is furnished as an exhibit and is not treated as "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors and the timeline for appointing a replacement, if applicable.
- Confirm the impact of the reduced board size on the Company's governance structure and committee assignments.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the resignation not included in the 8-K text.